Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation
The choice of drugs for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SS) is currently very limited. Data from a number of studies show that rituximab (RTM) can improve lung function and reduce the severity of skin fibrosis in patients with SS. Objective : to e...
Saved in:
Published in | Nauchno-prakticheskai͡a︡ revmatologii͡a Vol. 57; no. 3; pp. 265 - 273 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English Russian |
Published |
IMA PRESS LLC
11.07.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The choice of drugs for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SS) is currently very limited. Data from a number of studies show that rituximab (RTM) can improve lung function and reduce the severity of skin fibrosis in patients with SS.
Objective
: to evaluate the efficiency of RTM in a cohort of patients with SS-associated ILD after one-year follow-up. The indications for prescribing RTM were: 1) the inefficiency of standard therapy with glucocorticoids and immunosuppressants (ISs) or the impossibility of their use; 2) the early stage (first 3 years of the disease) with signs of poor prognosis, such as diffuse form, high skin scores (>14), male gender, rapid progression with a significant initial decline in forced vital capacity (FVC) and/or diffusion lung capacity (DLC), and a high anti-Scl-70 antibody positivity.
Subjects and methods.
The investigators selected a group of patients who had at least two assessment points at a 12-to-18 month interval (the mean follow-up period of 13±2 months) and took at least 1 g of RTM during this period. The investigation included 71 patients with a valid diagnosis of SS. Multi-slice spiral computed tomography (MSCT) revealed ILD in 90% of patients. The disease duration was 5.6±4.4 years. The presence of anti-Scl-70 antibodies was detected in 73% of patients. The mean cumulative dose of RTM was 1.43±0.6 g; 48 patients in Group 1 received ≤2 g of RTM (the mean dose, 1.1±0.1 g) and 23 patients in Group 2 took ≥2 g of RTM (mean dose, 2±0.6 g). Before starting treatment with RTM, all the patients received concomitant therapy with prednisone and 45% - with immunosuppressants.
Results and discussion.
The results assessed by a physician showed that good and moderate effects of the therapy were observed in 52 (73.2%) and 16 (22.6%) patients, respectively; no effect was seen in 3 (4.2%) patients. Overall, 95.8% of patients reported various degrees of improvement. There were significant changes as reductions in the disease activity index, skin scores, C-reactive protein and IgG levels, the number of patients with a high antinuclear antibody level, and the mean dose of prednisolone as well as increases in an oral aperture size, left ventricular ejection fraction, and 6-minute walk test scores. There were no changes in pulmonary artery systolic pressure and the HAQ DI. FVC increased from 77.35±19.9 to 82.6±20.7% (p=0.001). A minimal clinically significant increase in FVC ≥5% was noted in 41 (57.7%) people. The overall improvement in FVC (ΔFVC) reached 5.24%, while the changes were more significant in Group 2 (ΔFVC 8.98%) than in Group 1 (ΔFVC 3.75%; p=0.01). DLC remained stable, but there were significant group differences: ΔDLC was 3.75% in Group 2 and, conversely, decreased in Group 1 (1.6%; p=0005). The safety profile of the therapy was regarded as good and quite comparable with both the safety profile of ISs and the use of RTM in other trials. Infectious complications were recorded to be most common in 11 (15%) people. Of these, upper respiratory tract infections developed in 7 patients; plantar phlegmon occurred in one case; urinary tract infection and herpes zoster were detected in two and one cases, respectively.
The results
of this study confirm data from other studies that have demonstrated that RTM exerts a positive effect on SS-associated ILD. We were the first to show the association of positive changes in the measures of pulmonary function tests with the dose of RTM. |
---|---|
AbstractList | The choice of drugs for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SS) is currently very limited. Data from a number of studies show that rituximab (RTM) can improve lung function and reduce the severity of skin fibrosis in patients with SS.
Objective
: to evaluate the efficiency of RTM in a cohort of patients with SS-associated ILD after one-year follow-up. The indications for prescribing RTM were: 1) the inefficiency of standard therapy with glucocorticoids and immunosuppressants (ISs) or the impossibility of their use; 2) the early stage (first 3 years of the disease) with signs of poor prognosis, such as diffuse form, high skin scores (>14), male gender, rapid progression with a significant initial decline in forced vital capacity (FVC) and/or diffusion lung capacity (DLC), and a high anti-Scl-70 antibody positivity.
Subjects and methods.
The investigators selected a group of patients who had at least two assessment points at a 12-to-18 month interval (the mean follow-up period of 13±2 months) and took at least 1 g of RTM during this period. The investigation included 71 patients with a valid diagnosis of SS. Multi-slice spiral computed tomography (MSCT) revealed ILD in 90% of patients. The disease duration was 5.6±4.4 years. The presence of anti-Scl-70 antibodies was detected in 73% of patients. The mean cumulative dose of RTM was 1.43±0.6 g; 48 patients in Group 1 received ≤2 g of RTM (the mean dose, 1.1±0.1 g) and 23 patients in Group 2 took ≥2 g of RTM (mean dose, 2±0.6 g). Before starting treatment with RTM, all the patients received concomitant therapy with prednisone and 45% - with immunosuppressants.
Results and discussion.
The results assessed by a physician showed that good and moderate effects of the therapy were observed in 52 (73.2%) and 16 (22.6%) patients, respectively; no effect was seen in 3 (4.2%) patients. Overall, 95.8% of patients reported various degrees of improvement. There were significant changes as reductions in the disease activity index, skin scores, C-reactive protein and IgG levels, the number of patients with a high antinuclear antibody level, and the mean dose of prednisolone as well as increases in an oral aperture size, left ventricular ejection fraction, and 6-minute walk test scores. There were no changes in pulmonary artery systolic pressure and the HAQ DI. FVC increased from 77.35±19.9 to 82.6±20.7% (p=0.001). A minimal clinically significant increase in FVC ≥5% was noted in 41 (57.7%) people. The overall improvement in FVC (ΔFVC) reached 5.24%, while the changes were more significant in Group 2 (ΔFVC 8.98%) than in Group 1 (ΔFVC 3.75%; p=0.01). DLC remained stable, but there were significant group differences: ΔDLC was 3.75% in Group 2 and, conversely, decreased in Group 1 (1.6%; p=0005). The safety profile of the therapy was regarded as good and quite comparable with both the safety profile of ISs and the use of RTM in other trials. Infectious complications were recorded to be most common in 11 (15%) people. Of these, upper respiratory tract infections developed in 7 patients; plantar phlegmon occurred in one case; urinary tract infection and herpes zoster were detected in two and one cases, respectively.
The results
of this study confirm data from other studies that have demonstrated that RTM exerts a positive effect on SS-associated ILD. We were the first to show the association of positive changes in the measures of pulmonary function tests with the dose of RTM. The choice of drugs for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SS) is currently very limited. Data from a number of studies show that rituximab (RTM) can improve lung function and reduce the severity of skin fibrosis in patients with SS.Objective: to evaluate the efficiency of RTM in a cohort of patients with SS-associated ILD after one-year follow-up. The indications for prescribing RTM were: 1) the inefficiency of standard therapy with glucocorticoids and immunosuppressants (ISs) or the impossibility of their use; 2) the early stage (first 3 years of the disease) with signs of poor prognosis, such as diffuse form, high skin scores (>14), male gender, rapid progression with a significant initial decline in forced vital capacity (FVC) and/or diffusion lung capacity (DLC), and a high anti-Scl-70 antibody positivity.Subjects and methods. The investigators selected a group of patients who had at least two assessment points at a 12-to-18 month interval (the mean follow-up period of 13±2 months) and took at least 1 g of RTM during this period. The investigation included 71 patients with a valid diagnosis of SS. Multi-slice spiral computed tomography (MSCT) revealed ILD in 90% of patients. The disease duration was 5.6±4.4 years. The presence of anti-Scl-70 antibodies was detected in 73% of patients. The mean cumulative dose of RTM was 1.43±0.6 g; 48 patients in Group 1 received ≤2 g of RTM (the mean dose, 1.1±0.1 g) and 23 patients in Group 2 took ≥2 g of RTM (mean dose, 2±0.6 g). Before starting treatment with RTM, all the patients received concomitant therapy with prednisone and 45% - with immunosuppressants.Results and discussion. The results assessed by a physician showed that good and moderate effects of the therapy were observed in 52 (73.2%) and 16 (22.6%) patients, respectively; no effect was seen in 3 (4.2%) patients. Overall, 95.8% of patients reported various degrees of improvement. There were significant changes as reductions in the disease activity index, skin scores, C-reactive protein and IgG levels, the number of patients with a high antinuclear antibody level, and the mean dose of prednisolone as well as increases in an oral aperture size, left ventricular ejection fraction, and 6-minute walk test scores. There were no changes in pulmonary artery systolic pressure and the HAQ DI. FVC increased from 77.35±19.9 to 82.6±20.7% (p=0.001). A minimal clinically significant increase in FVC ≥5% was noted in 41 (57.7%) people. The overall improvement in FVC (ΔFVC) reached 5.24%, while the changes were more significant in Group 2 (ΔFVC 8.98%) than in Group 1 (ΔFVC 3.75%; p=0.01). DLC remained stable, but there were significant group differences: ΔDLC was 3.75% in Group 2 and, conversely, decreased in Group 1 (1.6%; p=0005). The safety profile of the therapy was regarded as good and quite comparable with both the safety profile of ISs and the use of RTM in other trials. Infectious complications were recorded to be most common in 11 (15%) people. Of these, upper respiratory tract infections developed in 7 patients; plantar phlegmon occurred in one case; urinary tract infection and herpes zoster were detected in two and one cases, respectively.The results of this study confirm data from other studies that have demonstrated that RTM exerts a positive effect on SS-associated ILD. We were the first to show the association of positive changes in the measures of pulmonary function tests with the dose of RTM. |
Author | Ovsyannikova, O. B. Garzanova, L. A. Koneva, O. A. Desinova, O. V. Glukhova, S. I. Aleksankin, A. P. Starovoitova, M. N. Ananyeva, L. P. Nasonov, E. L. Volkov, A. V. |
Author_xml | – sequence: 1 givenname: L. P. surname: Ananyeva fullname: Ananyeva, L. P. organization: V.A. Nasonova Research Institute of Rheumatology – sequence: 2 givenname: O. A. surname: Koneva fullname: Koneva, O. A. organization: V.A. Nasonova Research Institute of Rheumatology – sequence: 3 givenname: O. V. surname: Desinova fullname: Desinova, O. V. organization: V.A. Nasonova Research Institute of Rheumatology – sequence: 4 givenname: L. A. surname: Garzanova fullname: Garzanova, L. A. organization: V.A. Nasonova Research Institute of Rheumatology – sequence: 5 givenname: S. I. surname: Glukhova fullname: Glukhova, S. I. organization: V.A. Nasonova Research Institute of Rheumatology – sequence: 6 givenname: M. N. surname: Starovoitova fullname: Starovoitova, M. N. organization: V.A. Nasonova Research Institute of Rheumatology – sequence: 7 givenname: O. B. surname: Ovsyannikova fullname: Ovsyannikova, O. B. organization: V.A. Nasonova Research Institute of Rheumatology – sequence: 8 givenname: A. V. surname: Volkov fullname: Volkov, A. V. organization: V.A. Nasonova Research Institute of Rheumatology – sequence: 9 givenname: A. P. surname: Aleksankin fullname: Aleksankin, A. P. organization: V.A. Nasonova Research Institute of Rheumatology – sequence: 10 givenname: E. L. surname: Nasonov fullname: Nasonov, E. L. organization: V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University) |
BookMark | eNo9kdtOFTEUhhsDiQg8g32B0Z6mB-8MQSUh8UavmzU9SMnsdqftgPMUvrIzG8LValb_fO2f7wM6yyUHhD5S8okKQdlnasw4CKHFwAg1A5PjwBR_hy5eLww7eztr8R5dt_ZICKGKE6nIBfp3G2NwHZeIa-rL33SACZeM-0PAB8gphtahp5LbHgHX01PqK4bs8XGZDyVDXXFcstszOGV83NIh94afU3_AbW09HJLDzc2hlpbal40ehjVAxbHMc3keliMOTzAvp2eu0HmEuYXr13mJfn-7_XXzY7j_-f3u5uv94KjUMLBRUc3d6ITXk1eOgZYSqJ_k5BnEIPxk9MilUZQpw6OWYCYjR68NUVxN_BLdvXB9gUd7rFvvutoCyZ4Wpf6xUHvafm3jxLhiTlMZhPAjAUq4JmI0lBtHCWws9cJyW8NWQ3zjUWJPmuxuwO4G7K7Jbprspon_Bwahif4 |
CitedBy_id | crossref_primary_10_1134_S1607672924700856 crossref_primary_10_14412_1995_4484_2020_42_47 crossref_primary_10_20514_2226_6704_2021_11_1_72_75 crossref_primary_10_47360_1995_4484_2023_199_206 crossref_primary_10_47360_1995_4484_2020_395_400 crossref_primary_10_47360_1995_4484_2022_1 crossref_primary_10_14412_1995_4484_2019_3_40 crossref_primary_10_14412_1996_7012_2023_5_53_60 crossref_primary_10_47360_1995_4484_2022_57_63 crossref_primary_10_14412_1996_7012_2020_4_91_97 crossref_primary_10_47360_1995_4484_2020_520_531 crossref_primary_10_47360_1995_4484_2023_466_474 |
Cites_doi | 10.1136/ard.2006.062901 10.1093/qjmed/hcm052 10.5021/ad.2015.27.1.1 10.1136/ard.62.2.146 10.1002/art.23902 10.1186/ar3125 10.1016/j.semarthrit.2014.09.002 10.1186/ar2965 10.14412/1995-4484-2014-495-506 10.1016/j.autrev.2015.10.005 10.1002/art.22204 10.1002/art.1780370903 10.1093/rheumatology/kev016 10.1136/ard.2008.096677 10.1136/annrheumdis-2013-204424 10.1016/0002-9343(87)90501-8 10.3899/jrheum.120778 10.1164/rccm.201709-1845OC 10.1016/S2213-2600(16)30152-7 10.5301/jsrd.5000207 10.1002/art.34427 10.1056/NEJMoa055120 10.1016/j.semarthrit.2016.10.003 10.1136/rmdopen-2016-000384 10.1186/s13063-017-2016-2 10.1002/art.40560 10.1093/rheumatology/ken313 10.2147/DDDT.S139248 10.1001/archinte.1973.03650100028006 10.1093/rheumatology/kex203 10.1164/rccm.2106012 10.1016/j.autrev.2015.07.008 10.1002/art.30467 10.1007/s40265-015-0491-x 10.1164/ajrccm.166.1.at1102 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q 10.1136/ard.60.6.592 10.1016/j.autrev.2017.12.010 10.1016/j.autrev.2011.04.013 10.1136/ard.2005.050187 10.1136/ard.2008.095463 10.1002/art.24249 10.1016/0002-9343(82)90732-X 10.1136/annrheumdis-2013-204522 10.1016/j.imlet.2018.01.002 10.1093/rheumatology/ker269 10.1136/annrheumdis-2016-209909 |
ContentType | Journal Article |
DBID | AAYXX CITATION DOA |
DOI | 10.14412/1995-4484-2019-265-273 |
DatabaseName | CrossRef DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1995-4492 |
EndPage | 273 |
ExternalDocumentID | oai_doaj_org_article_fb2372c816e44d50a10380459139c10a 10_14412_1995_4484_2019_265_273 |
GroupedDBID | 5VS 642 AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS BCNDV CITATION GROUPED_DOAJ M~E |
ID | FETCH-LOGICAL-c168a-257183c5c4d8bd7c2a866a1db6bd2afe4db985369712793f86a9b965d890737b3 |
IEDL.DBID | DOA |
ISSN | 1995-4484 |
IngestDate | Mon Oct 21 19:39:55 EDT 2024 Fri Aug 23 04:16:07 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English Russian |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c168a-257183c5c4d8bd7c2a866a1db6bd2afe4db985369712793f86a9b965d890737b3 |
OpenAccessLink | https://doaj.org/article/fb2372c816e44d50a10380459139c10a |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_fb2372c816e44d50a10380459139c10a crossref_primary_10_14412_1995_4484_2019_265_273 |
PublicationCentury | 2000 |
PublicationDate | 2019-07-11 |
PublicationDateYYYYMMDD | 2019-07-11 |
PublicationDate_xml | – month: 07 year: 2019 text: 2019-07-11 day: 11 |
PublicationDecade | 2010 |
PublicationTitle | Nauchno-prakticheskai͡a︡ revmatologii͡a |
PublicationYear | 2019 |
Publisher | IMA PRESS LLC |
Publisher_xml | – name: IMA PRESS LLC |
References | ref13 ref12 ref15 ref14 ref53 ref52 ref11 ref10 ref17 ref16 ref19 ref18 ref51 ref50 ref46 ref45 ref48 ref47 ref42 ref41 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 ref35 ref34 ref37 ref36 ref31 ref30 ref33 ref32 ref2 ref1 ref39 ref38 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 |
References_xml | – ident: ref13 doi: 10.1136/ard.2006.062901 – ident: ref37 doi: 10.1093/qjmed/hcm052 – ident: ref2 doi: 10.5021/ad.2015.27.1.1 – ident: ref42 doi: 10.1136/ard.62.2.146 – ident: ref22 doi: 10.1002/art.23902 – ident: ref48 doi: 10.1186/ar3125 – ident: ref30 doi: 10.1016/j.semarthrit.2014.09.002 – ident: ref6 doi: 10.1186/ar2965 – ident: ref10 doi: 10.14412/1995-4484-2014-495-506 – ident: ref25 doi: 10.1016/j.autrev.2015.10.005 – ident: ref39 doi: 10.1002/art.22204 – ident: ref47 doi: 10.1002/art.1780370903 – ident: ref49 doi: 10.1093/rheumatology/kev016 – ident: ref23 doi: 10.1136/ard.2008.096677 – ident: ref12 doi: 10.1136/annrheumdis-2013-204424 – ident: ref45 doi: 10.1016/0002-9343(87)90501-8 – ident: ref8 doi: 10.3899/jrheum.120778 – ident: ref20 doi: 10.1164/rccm.201709-1845OC – ident: ref26 – ident: ref41 doi: 10.1016/S2213-2600(16)30152-7 – ident: ref24 doi: 10.5301/jsrd.5000207 – ident: ref36 doi: 10.1002/art.34427 – ident: ref40 doi: 10.1056/NEJMoa055120 – ident: ref31 doi: 10.1016/j.semarthrit.2016.10.003 – ident: ref29 doi: 10.1136/rmdopen-2016-000384 – ident: ref3 – ident: ref53 doi: 10.1186/s13063-017-2016-2 – ident: ref51 doi: 10.1002/art.40560 – ident: ref18 doi: 10.1093/rheumatology/ken313 – ident: ref34 doi: 10.2147/DDDT.S139248 – ident: ref44 doi: 10.1001/archinte.1973.03650100028006 – ident: ref19 doi: 10.1093/rheumatology/kex203 – ident: ref43 doi: 10.1164/rccm.2106012 – ident: ref32 – ident: ref9 doi: 10.1016/j.autrev.2015.07.008 – ident: ref50 doi: 10.1002/art.30467 – ident: ref33 doi: 10.1007/s40265-015-0491-x – ident: ref21 doi: 10.1164/ajrccm.166.1.at1102 – ident: ref15 doi: 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q – ident: ref17 doi: 10.1136/ard.60.6.592 – ident: ref38 doi: 10.1016/j.autrev.2017.12.010 – ident: ref1 doi: 10.1016/j.autrev.2011.04.013 – ident: ref16 doi: 10.1136/ard.2005.050187 – ident: ref7 doi: 10.1136/ard.2008.095463 – ident: ref28 – ident: ref5 doi: 10.1002/art.24249 – ident: ref46 doi: 10.1016/0002-9343(82)90732-X – ident: ref27 doi: 10.1136/annrheumdis-2013-204522 – ident: ref4 doi: 10.1016/j.imlet.2018.01.002 – ident: ref11 doi: 10.1093/rheumatology/ker269 – ident: ref52 doi: 10.1136/annrheumdis-2016-209909 – ident: ref35 – ident: ref14 |
SSID | ssj0001730670 |
Score | 2.128265 |
Snippet | The choice of drugs for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SS) is currently very limited. Data from a number... |
SourceID | doaj crossref |
SourceType | Open Website Aggregation Database |
StartPage | 265 |
SubjectTerms | anti-b cell therapy interstitial lung disease rituximab systemic sclerosis |
Title | Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation |
URI | https://doaj.org/article/fb2372c816e44d50a10380459139c10a |
Volume | 57 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PSx0xEA7Fg3gRay3-qsyh1-Amu5tNvNlSEaE9KXgL-QkP6nuPty72_RX9lzuTXe3z5MVrCEnIfMN8k2S-MPY1ZR9l6Dyvgo68QQLCdYqSJxGMyEUjrrzy_aWu75qb-_Z-46svehM2ygOPG3eevaw7GbRQqWliWzlS9EYeQnKWQVQjNRLtRjJVTlc6osKlGpJKkDEHaabHXRj-5flLI4JEGC5LXVb9KjRtKPiXUHO1x3YnjgiX49o-sg-rYZ9t_5xuwT-xv6PkMCwyYGo__Jk9OA-LOSCXA5KzyKkfL9h76kKVC_RBBLh5hOXwG3HnVmuggEZ9YDaHSVy1BzqVhVHceRagx9lxpbP-AkdPfI1OARlxs3jiwxL-64QfsLurH7ffr_n0sQIPQmnH0U3Rk0Mbmqh97IJ0WiknoldoOJdTE73BMK5MJyT6b9bKGW9UGzWm0nXn689sa44THzLQSYvcmRxrXzexdqYKyMFkrk0MIcnqiFXPe2qXo36GpbyDzGDJDJbMYMkMFs1g0QxH7Bvt_Ut3EsAuDQgLO8HCvgWL4_cY5ITtFHyQjqY4ZVuPqyF9QQ7y6M8K3P4B9E3V2Q |
link.rule.ids | 315,786,790,870,2115,27955,27956 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+rituximab+on+the+manifestations+of+activity+and+pulmonary+function+in+patients+with+systemic+sclerosis%3A+one-year+follow-up+evaluation&rft.jtitle=Nauchno-prakticheskai%CD%A1a%EF%B8%A1+revmatologii%CD%A1a&rft.au=L.+P.+Ananyeva&rft.au=O.+A.+Koneva&rft.au=O.+V.+Desinova&rft.au=L.+A.+Garzanova&rft.date=2019-07-11&rft.pub=IMA+PRESS+LLC&rft.issn=1995-4484&rft.eissn=1995-4492&rft.volume=57&rft.issue=3&rft.spage=265&rft.epage=273&rft_id=info:doi/10.14412%2F1995-4484-2019-265-273&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_fb2372c816e44d50a10380459139c10a |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1995-4484&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1995-4484&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1995-4484&client=summon |